Buysiders brush off midterms

Although drug pricing reform is one of the few bipartisan issues that a divided Congress might be able to agree upon, key biotech and pharma indexes have largely shrugged off the midterm results in a sign that it’s business as usual for biopharma investors.

After rising 1-3% on Wednesday, biotech indexes gave back some of their initial gains. Since Tuesday's close, the NASDAQ Biotechnology Index (NBI), SPDR S&P Biotech ETF (XBI) and the BioCentury 100 have added 1%, and the NYSE Arca Biotechnology Index (BTK) is unchanged...